» Articles » PMID: 8420443

Veno-occlusive Disease of the Liver and Multiorgan Failure After Bone Marrow Transplantation: a Cohort Study of 355 Patients

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 1993 Feb 15
PMID 8420443
Citations 234
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the incidence and clinical course of veno-occlusive disease of the liver (VOD) after bone marrow transplantation and to analyze risk factors for severe VOD.

Design: Cohort study of 355 consecutive patients.

Setting: A bone marrow transplantation center.

Measurements: Each patient was prospectively evaluated for VOD, and many risk factors for severe VOD were analyzed using logistic regression models. The relation of VOD to renal and cardiopulmonary failure was analyzed using time-dependent proportional hazards models.

Results: Veno-occlusive disease developed in 190 of 355 patients (54%; 95% CI, 48% to 59%): Fifty-four patients had severe VOD and 136 had mild or moderate VOD. Independent variables derived from a multivariate model for predicting severe VOD included elevated transaminase values before transplantation (relative risk, 4.6; P < 0.0001); vancomycin therapy during cytoreductive therapy (relative risk, 2.9; P = 0.003); cytoreductive therapy with a high-dose regimen (relative risk, 2.8; P = 0.01); acyclovir therapy before transplantation (relative risk, 4.8; P = 0.02); mismatched or unrelated donor marrow (relative risk, 2.4; P = 0.02); and previous radiation therapy to the abdomen (relative risk, 2.2; P = 0.04). Vancomycin therapy was a marker for persistent fever. Multiorgan failure was more frequent among patients with VOD and usually followed the onset of liver disease.

Conclusions: Veno-occlusive disease, which developed in 54% of bone marrow transplant recipients, is frequently associated with renal and cardiopulmonary failure. Pretransplant transaminase elevations, use of high-dose cytoreductive therapy, and persistent fever during cytoreductive therapy are independent predictors of severe VOD.

Citing Articles

Outcomes in patients undergoing hematopoietic stem cell transplantation for myelodysplastic syndromes.

Karumathil S, Kulkarni U, Selvarajan S, Lionel S, Devasia A, Aboobacker F Blood Cell Ther. 2025; 8(1):147-159.

PMID: 40061177 PMC: 11883483. DOI: 10.31547/bct-2024-002.


Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Paediatric Patients Who Did Not Receive Haematopoietic Stem Cell Transplantation: Case Reports of Patients From a German Academic Hospital.

Kleinschmidt K, Troeger A, Foll J, Hanafee-Alali T, Jakob M, Kramer S EJHaem. 2025; 6(1):e1094.

PMID: 39866932 PMC: 11756966. DOI: 10.1002/jha2.1094.


Busulfan conditioning and prognostic impact of jaundice in late-onset sinusoidal obstruction syndrome following allogeneic hematopoietic cell transplantation.

Takagi S, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y Bone Marrow Transplant. 2024; 60(3):418-421.

PMID: 39715812 DOI: 10.1038/s41409-024-02501-1.


Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review.

Fan L, Stewart F, Ruiz K, Devani D, Fusco N, Gill M Heliyon. 2024; 10(20):e36883.

PMID: 39640784 PMC: 11619986. DOI: 10.1016/j.heliyon.2024.e36883.


Role of Endoscopic Techniques in the Diagnosis of Complications of Allogeneic Hematopoietic Stem Cell Transplantation: A Review of the Literature.

Bangolo A, Dey S, Nagesh V, Gumer K, Avetisyan L, Islam S J Clin Med. 2024; 13(15).

PMID: 39124609 PMC: 11313381. DOI: 10.3390/jcm13154343.